EC approves Alprolix for the treatment of haemophilia B
13 May 2016 | By Victoria White, Digital Content Producer
The European Commission has approved Alprolix (rFIXFc) for the treatment of haemophilia B and maintained its orphan designation...
List view / Grid view
13 May 2016 | By Victoria White, Digital Content Producer
The European Commission has approved Alprolix (rFIXFc) for the treatment of haemophilia B and maintained its orphan designation...
3 May 2016 | By Victoria White, Digital Content Producer
The new company, to be named at a later date, will focus on the discovery and development of therapies for the treatment of haemophilia...
23 March 2016 | By Victoria White
CSL Behring’s Idelvion and Sobi/Biogen’s Alprolix will compete intensely for a share of the haemophilia B market following their expected European approvals...